EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC) Meeting Abstract
| Authors: | Powles, T. B.; Perez Valderrama, B.; Gupta, S.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Iyer, G.; Vulsteke, C.; Park, S. H.; Shin, S. J.; Castellano Gauna, D. E.; Fornarini, G.; Li, J. R.; Gumus, M.; Mar, N.; Narayanan, S.; Yu, X.; Gorla, S.; Homet Moreno van der Heijden, B. M. S. |
| Abstract Title: | EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC) |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S1340 |
| Language: | English |
| ACCESSION: | WOS:001087480203591 |
| DOI: | 10.1016/j.annonc.2023.10.106 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA6 -- Source: Wos |
